![]() |
Figure 6: Ta1 improves survival in HCC treated with TACE. In a study with 32 Chinese patients being treated with TACE for HCC, the addition of Ta1 to the treatment (1.6 mg daily for 10 days) provided a significant increase in survival compared to historical controls at 6, 9, and 12 months after TACE [145,146]. |